In the BioHarmony Drug Report Database

"Preview" Icon

Haloperidol decanoate

Haldol (haloperidol decanoate) is a small molecule pharmaceutical. Haloperidol decanoate was first approved as Haldol on 1986-01-14. It is used to treat child behavior disorders, psychotic disorders, schizophrenia, schizophrenia spectrum and other psychotic disorders, and substance withdrawal syndrome amongst others in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A, D(4) dopamine receptor, D(3) dopamine receptor, and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 7, histamine H1 receptor, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1D, D(1B) dopamine receptor, potassium voltage-gated channel subfamily H member 1, and G protein-activated inward rectifier potassium channel 2.

 

Trade Name

 

Haldol
 

Common Name

 

haloperidol decanoate
 

ChEMBL ID

 

CHEMBL1200986
 

Indication

 

child behavior disorders, psychotic disorders, schizophrenia, schizophrenia spectrum and other psychotic disorders, substance withdrawal syndrome, tourette syndrome, vomiting
 

Drug Class

 

Antipsychotics (haloperidol type)

Image (chem structure or protein)

Haloperidol decanoate structure rendering